

**PCT****WORLD INTELLECTUAL PROPERTY ORGANIZATION**

International Bureau

**INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)**

<b>(51) International patent classification<sup>6</sup>:</b>  <b>A61K 39/21, 39/245, 39/12, 39/00, 39/118, 39/02 // C07K 14/16</b>	<b>A1</b>	<b>(11) International publication number:</b> <b>WO 00/00217</b>  <b>(43) International publication date:</b>  <b>6 January 2000 (06.01.00)</b>
<b>(21) International application number:</b> <b>PCT/FR99/01539</b>  <b>(22) International filing date:</b> <b>25 June 1999 (25.06.99)</b>  <b>(30) Data relating to the priority:</b> <b>98/08,353 26 June 1998 (26.06.98) FR</b>  <b>(71) Applicant (for all designated States except US):</b> <b>PASTUER MERIEUX SERUMS &amp; VACCINS</b> <b>[FR/FR]; 58, avenue Leclerc, F-69007 Lyon (FR).</b>  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (US only):</b> <b>JOURDIER, Thérèse</b> <b>[FR/FR]; Le Grillon, Bâtiment B, Chemin de</b> <b>Chantegrillet, F-69340 Francheville (FR). MOSTE,</b> <b>Catherine [FR/FR]; 7, avenue Louis Momet, F-69260</b> <b>Charbonnière les Bains (FR). MEIGNIER, Bernard</b> <b>[FR/FR]; 26, rue du 8 Mai 1945, F-69510 Thurins</b> <b>(FR).</b>  <b>(74) Representative:</b> <b>KERNEIS, Danièle; Pasteur Merriex</b> <b>Connaught, Direction de la Propriété Industrielle,</b> <b>58, avenue Leclerc, F-69007 Lyon (FR).</b>		<b>(81) Designated states:</b> <b>AE. AL. AM. AT. AU. AZ. BA. BB. BG. BR. BY. CA. CH. CN. CU. CZ. DE. DK. EE. ES. FI. GB. GD. GE. GH. GM. HR. HU. ID. IL. IN. IS. JP. KE. KG. KP. KR. KZ. LC. LK. LR. LS. LT. LU. LV. MD. MG. MK. MN. MW. MX. NO. NZ. PL. PT. RO. RU. SD. SE. SG. SI. SK. SL. TJ. TM. TR. TT. UA. UG. US. UZ. VN. YU. ZA. ZW, ARIPO Patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b>  <b>Published</b> <b>With the International Search Report.</b> <b>Before expiry of the period provided for amending the claims; will be republished if such amendments are received.</b>
<p style="text-align: center;"><b>As printed</b></p> <p><b>(54) Title: <u>MUCOSAL TARGETING IMMUNISATION</u></b></p> <p><b>(54) Titre: <u>IMMUNISATION A CIBLAGE MUCOSAL</u></b></p> <p><b>(57) Abstract</b></p> <p>The invention concerns the use of an immunogen specific of a pathogenic agent having a gateway in a mucous membrane for producing an immunogenic composition to be administered to a human by parenteral route at the surface of part of the body distinct from the mucous membrane so as to directly develop a local response in IgA, IgG and/or IgM antibody in said mucous membrane.</p> <p><b>(57) Abrégé</b></p> <p>Utilisation d'immunogène spécifique d'un agent pathogène ayant une porte d'entrée au niveau d'une muqueuse pour la production d'une composition immunogène destinée à être administrée chez l'homme par voie parentérale à la surface d'une partie du corps distincte de ladite muqueuse, de manière à directement développer une réponse locale en anticorps IgA, IgG et/ou IgM au niveau de ladite muqueuse.</p>		